4 Health Care Stocks On The Rise

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 91 points (-0.6%) at 15,838 as of Wednesday, Jan. 29, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 929 issues advancing vs. 2,026 declining with 145 unchanged.

The Health Care sector currently sits down 0.5% versus the S&P 500, which is down 0.4%. Top gainers within the sector include Illumina ( ILMN), up 3.4%, Regeneron Pharmaceuticals ( REGN), up 2.2%, Teva Pharmaceutical Industries ( TEVA), up 2.1%, WellPoint ( WLP), up 2.3% and Vertex Pharmaceuticals ( VRTX), up 1.8%. On the negative front, top decliners within the sector include Bristol-Myers Squibb Company ( BMY), down 1.3%, Merck ( MRK), down 1.2%, Actavis ( ACT), down 0.9%, Covidien ( COV), down 0.9% and AstraZeneca ( AZN), down 0.7%.

TheStreet would like to highlight 4 stocks pushing the sector higher today:

4. Medivation ( MDVN) is one of the companies pushing the Health Care sector higher today. As of noon trading, Medivation is up $9.22 (12.2%) to $85.00 on heavy volume. Thus far, 4.0 million shares of Medivation exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $82.60-$87.46 after having opened the day at $86.00 as compared to the previous trading day's close of $75.78.

Medivation, Inc., a biopharmaceutical company, focuses on development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. Medivation has a market cap of $5.5 billion and is part of the drugs industry. Shares are up 18.7% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts who rate Medivation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Medivation as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full Medivation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Humana ( HUM) is up $1.91 (2.0%) to $97.93 on average volume. Thus far, 778,140 shares of Humana exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $94.20-$98.31 after having opened the day at $95.18 as compared to the previous trading day's close of $96.02.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in three segments: Retail, Employer Group, and Healthcare Services. Humana has a market cap of $15.0 billion and is part of the health services industry. The company has a P/E ratio of 10.6, below the S&P 500 P/E ratio of 17.7. Shares are down 7.0% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts who rate Humana a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Intuitive Surgical ( ISRG) is up $7.85 (1.9%) to $417.39 on light volume. Thus far, 169,897 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 502,700 shares. The stock has ranged in price between $405.02-$418.33 after having opened the day at $405.02 as compared to the previous trading day's close of $409.54.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $15.6 billion and is part of the health services industry. The company has a P/E ratio of 24.4, above the S&P 500 P/E ratio of 17.7. Shares are up 6.6% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Intuitive Surgical a buy, 4 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Intuitive Surgical Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Allergan ( AGN) is up $0.80 (0.7%) to $114.79 on light volume. Thus far, 762,151 shares of Allergan exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $113.25-$115.73 after having opened the day at $113.86 as compared to the previous trading day's close of $113.99.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $33.8 billion and is part of the drugs industry. The company has a P/E ratio of 26.9, above the S&P 500 P/E ratio of 17.7. Shares are up 2.6% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts who rate Allergan a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

Second-Quarter Picks and Pans

Second-Quarter Picks and Pans

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors